As the COVID-19 epidemic spread across the U.S. earlier this year, Nurx, like most other digital providers of healthcare and prescription services, saw a huge spike in demand.
Now, with $22.5 million in new financing and a surging annual run rate that could see the company hit $150 million in revenue, the company is emerging as the largest digital practice for women’s health.
“We saw this tremendous surge in need for our contraception and sensitive health services,” says Nurx chief executive Varsha Rao .
The growth hasn’t come without controversy. Only last year, a New York Times article pointed to corner cutting at the startup, which boasts Chelsea Clinton as an investor and advisor.
Undeterred, Rao said the company has now seen tremendous acceleration in all areas of its business. It’s now providing care to more than 300,000 patients on a monthly basis, boasts that $150 million run rate and